RB1, ERBB2, and CCNE1 alterations were noted in patients who were not responsive to abemaciclib, suggesting that tumor biomarkers may help in the selection of patients who will respond to a rechallenge to a CDK4/6i. This evidence concerns the gene CDK4 and neoplasm.